Clinical Trial Search

Primary: Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1 — 12.7; 13.5 mIU/mL

Primary: Multiple Sleep Latency Test (MSLT) — 3.1; 0.4 Minutes — p=<0.0001

Primary: Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring — -21.4 mm Hg — p=<0.0001

Primary: Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21). — 2.6; 1.8; 2.5; 1.3 g/dL

Primary: CFU (Colony Forming Units) — 7.18; 6.94 number of colony forming units — p=0.05

Primary: Responders — 17; 28; 9 Participants

Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001

Primary: Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment — -10.1; -6.5 Score on a…

Primary: Intraocular Pressures (IOPs) at Baseline — 22.57; 22.98; 20.86; 21.78 mmHg

Primary: Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) — -6.0; -8.9; -12.0 mm Hg

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) — -10.8; -6.3; -7.2 mmHg

Primary: Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline. — -2.1; -2.9 number of episodes per 24 hours — p=0.0002

Primary: Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo — -15.8; 2.1…

Primary: Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. — 80.8; 87.0; 46.0 percentage of subjects

Primary: Mean Creatinine Clearance Rate — 56.800; 53.449 ml/min — p=0.6081